AI-generated summary
This review examines animal and human studies of emerging neuromodulation methods for Alzheimer's disease, including deep brain stimulation, transcranial magnetic and electrical stimulation, ultrasound, photobiomodulation, and sensory stimulation. The authors report that evidence for safety and efficacy is variable and often very limited, with most human data coming from small clinical trials. They identify areas where further work is needed before clinical translation.
- Who or what was studied
- People with Alzheimer's disease and animal models of the disease
- Limits stated in the abstract
- Most human evidence comes from small clinical trials, and the evidence for safety and efficacy is variable and in many cases very limited.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Neuromodulation, Transcranial magnetic stimulation, Photobiomodulation, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.